📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) 👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3 🖇️ for explanation: authors.elsevier.com/sd/article/S...

Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event. 🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky

A huge thank you to all the Friends of the Young Talent Group joining today’s meeting in Vienna! As young voices shaping the future of GI, your involvement makes a real difference! @annemariegrima.bsky.social @hannasternby.bsky.social #myUEGcommunity

Can we please take a moment and congratulate my colleague @georg-semmler.bsky.social with publication of his study on Tangier disease, an extremely rare disease caused by ABCA1 defect with no existing treatment? Great journey with lipidomids & metabolomics of TD 🧪 academic.oup.com/jcem/advance...

It was a great honor and experience to serve on a PhD committee of now PhDr. Kamilla Hejn of @ravnskjaer-lab.bsky.social together with Prof. @joannakalucka.bsky.social and @SorenFiskerSchmidt. also happy to meet up with @georg-semmler.bsky.social during his sabbatical in 🇩🇰 @majathiele.bsky.social

New from us: Screening for advanced fibrosis due to MASLD in T2D - the SCANDIA study. Out now in @LancetGastroHep: authors.elsevier.com/a/1kFtR8nByr... What did we do and find? Summarized in this thread:

🎯🎯LiverPRO🎯🎯 Another benchmark for non-invasive risk assessment for chronic liver disease in the primary care (but maybe not only there?) ▶️ LancetGH @robbrierley.bsky.social ky.social www.thelancet.com/journals/lan... Congrats Katrine Lindvig, Maja Thiele & team! #GastroSky #LiverSky #MedSky

Very grateful to have received the Award of Excellence from the Austrian Ministry of Education, Sience and Resarch for my PhD thesis on "Non-invasive risk stratification in chronic liver disease". Non-invasive liver disease assessment = the future 🚀 @Medical University of Vienna shorturl.at/Q1Aos

#LiverSky Useful tip... There's no 'bookmark' function in Bluesky currently. But there is a nice work-around: 1) Reply to the post of interest with a📌emoji 2) Click on this link bsky.app/profile/did:... 3) Click 'Pin to Home' This will collate📌posts in a tab on your home screen + ⬆️ engagement.